



# Combat Drugs Limited

Regd. Off: 9-109/9, Plot No.112, Road No.14, Gayatri Nagar, Bouduppall, R.R.District -500039, TS  
Ph: +91-40-66200100 / 65523363 Url: www.combatdrugs.in Email: info@combatdrugs.in  
CIN No.: L24230TG1986PLC006781 TIN: 36690236431 D.L.No.: TG/15/04/2016-14766

14/02/2017

To,  
The General Manager  
Department of Corporate Services  
BSE Limited  
P. J. Towers, Dalal Street,  
Mumbai – 400001

Sir,

Sub: Outcome of Board Meeting – Approval of Quarterly Results  
(Quarter ended 31<sup>st</sup> December, 2016)

Pursuant to Regulation 29 & 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that at the meeting of the Board of Directors of the company held today ie; 14<sup>th</sup> February, 2017, the Statement of Un-Audited Financial Results for the quarter ended 31<sup>st</sup> December, 2016 was approved and taken on record along with the Limited Review Report for the period issued by the Statutory Auditors of the company.

Please find enclosed the following in respect of the above said:

1. Statement of Un-Audited Financial Results for the Quarter ended 31<sup>st</sup> Dec, 2016.
2. Limited Review Report of the Auditors on Quarterly Financial Results pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This is for your information and records.

Thanking You



Yours Sincerely,

For **COMBAT DRUGS LIMITED**

Kiran Kumar K

**COMPLIANCE OFFICER**



<b>COMBAT DRUGS LIMITED</b> (CIN NO. CL23230TG1986PLC006781)		Regd.off.:9-109/9, Plot No.112, Rd No.14, Gayatri Nagar, Bouduppall (V), R.R.Dist Hyderabad ,Telangana ,500039		Ph: 040-65523363 / 66200100 URL: www.combatdrugs.in Mail: info@combatdrugs.in		
<b>UNAUDITED FINANCIAL RESULTS FOR THE QUARTER &amp; NINE MONTHS ENDED 31ST DECEMBER, 2016</b> Amount - Rs. In lakhs						
Particulars	Quarter Ended			9 Months Ended		Year Ended
	31.12.2016	30.09.2016	31.12.2015	31.12.2016	31.12.2015	31.03.2016
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>PART - I</b>						
<b>1. Income from Operations</b>						
1 (a) Net Sales/Income from Operations (net of excise duty)	15.31	9.85	9.91	28.23	16.84	22.30
(b) Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
<b>Total income from operations (net)</b>	<b>15.31</b>	<b>9.85</b>	<b>9.91</b>	<b>28.23</b>	<b>16.84</b>	<b>22.30</b>
<b>2. Expenses</b>						
a. Cost of materials consumed	12.00	5.13	2.83	19.70	8.10	11.30
b. Purchase of stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
c. Changes in inventories of Finished goods, work-in-progress and stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
d. Employees benefits expense	7.02	5.09	1.53	16.19	4.59	12.38
e. Depreciation	0.00	0.00	2.85	0.00	8.56	8.56
f. Expired stocks	0.00	0.00	0.00	0.00	0.00	39.92
g. Other expenses	1.57	5.45	4.68	11.58	17.93	78.46
<b>Total</b>	<b>20.59</b>	<b>15.67</b>	<b>11.89</b>	<b>47.47</b>	<b>39.18</b>	<b>150.62</b>
3 <b>Profit / (Loss) from Operations before Other Income, finance costs and Exceptional Items</b>	(5.28)	(5.82)	(1.98)	(19.24)	(22.34)	(128.32)
4 Other Income	0.00	0.00	0.25	0.00	0.40	0.55
5 <b>Profit / (Loss) from ordinary activities before finance costs and Exceptional Items (3+4)</b>	(5.28)	(5.82)	(1.73)	(19.24)	(21.94)	(127.77)
6 Finance costs	0.00	0.00	0.00	0.00	0.00	0.00
7 <b>Profit / (Loss) from ordinary activities after finance costs but before Exceptional Items (5-6)</b>	(5.28)	(5.82)	(1.73)	(19.24)	(21.94)	(127.77)
8 Exceptional items	0.00	0.00	0.00	0.00	28.81	0.00
9 <b>Profit / (Loss) from Ordinary Activities before tax (7+8)</b>	(5.28)	(5.82)	(1.73)	(19.24)	(50.75)	(127.77)
10 Tax expense	0.00	0.00	0.00	0.00	0.00	0.00
11 <b>Net Profit / (Loss) from Ordinary Activities after tax (9+10)</b>	(5.28)	(5.82)	(1.73)	(19.24)	(50.75)	(127.77)
12 Extraordinary Item (net of tax expenses)	0.00	0.00	0.00	0.00	0.00	0.00
13 <b>Net Profit / (Loss) for the period (11-12)</b>	<b>(5.28)</b>	<b>(5.82)</b>	<b>(1.73)</b>	<b>(19.24)</b>	<b>(50.75)</b>	<b>(127.77)</b>
14 <b>Share of Profit / (Loss) of associates</b>	0.00	0.00	0.00	0.00	0.00	0.00
15 Minority interest	0.00	0.00	0.00	0.00	0.00	0.00
16 <b>Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13+14+15)</b>	(5.28)	(5.82)	(1.73)	(19.24)	(50.75)	(127.77)
17 Paid-up equity share capital (Face value of the Share shall be indicated) - Face value Rs. 10/-	800.00	800.00	800.00	800.00	800.00	800.00
18 Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	0.00	0.00	0.00	-	0.00	0.00
19 i) Earnings per Share (before extraordinary items) of Rs. /- each (not annualised):						
(a) Basic	(0.07)	(0.07)	0.00	(0.24)	(0.06)	(1.60)
(b) Diluted	(0.07)	(0.07)	0.00	(0.24)	(0.06)	(1.60)
ii) Earning per share (after extraordinary items)						
(a) Basic	(0.07)	(0.07)	0.00	(0.24)	(0.06)	(1.60)
(b) Diluted	(0.07)	(0.07)	0.00	(0.24)	(0.06)	(1.60)
<b>Notes</b>						
1.The above Financial Results as recommended by the Audit Committee were considered and approved by the Board of Directors at their meeting held on 14th Feb, 2017.						
2. The Company is operating in only one segment i.e, Pharmaceuticals and hence segment – wise reporting is not made.						
3. Previous year/s / period's figures have been regrouped / rearranged / recasted wherever necessary.						
<b>For and on behalf of the Board of Directors</b>						
 <b>DIRECTOR</b>						
						
Place: Hyderabad						
Date : 14.02.2017						

**M. ANANDAM & CO.,**  
CHARTERED ACCOUNTANTS

**INDEPENDENT AUDITORS' REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS**

To  
The Board of Directors of  
Combat Drugs Limited

We have reviewed the accompanying Statement of Unaudited Financial Results of Combat Drugs Limited for the Quarter and nine months ended 31<sup>st</sup> December, 2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Unaudited Financial Results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Circular No. CIR/CFD/CMD/15/2015 dated 30<sup>th</sup> November, 2015 and SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5<sup>th</sup> July, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M. Anandam & Co.,  
Chartered Accountants  
(FRN: 000125S)

  
A.V. Sadasiva  
Partner  
Membership No.018404



Place: Secunderabad  
Date: 14<sup>th</sup> February, 2017